Shopping Cart 0
Cart Subtotal
USD 0

Grifols SA (GRF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. The company offers its products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA (GRF)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10

Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Grifols SA, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12

Partnerships 14

Araclon Biotech Enters into Agreement with TFS International 14

Grifols and GigaGen Enter into Research Agreement 15

Grifols Enters into Agreement with MassBiologics 16

Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17

Licensing Agreements 18

Grifols Enters Into Licensing Agreement With Aradigm 18

ThromboGenics Enters into Licensing Agreement with Grifols 20

Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21

Equity Offering 22

Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 23

Debt Offering 24

Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24

Grifols Completes Public Offering Of Bonds Due 2022 For USD 1 Billion 25

Acquisition 26

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27

Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28

Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29

Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30

Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31

Alken Asset Management Sells 2.72% Stake In Grifols For USD 227 Million 32

Grifols Completes Acquisition Of 35% Stake In Aradigm For USD 26 Million 33

Grifols Acquires 60% Stake In Progenika Biopharma For USD 48 Million 34

Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35

Grifols Acquires 51% Stake In Araclon Biotech 36

Grifols SA-Key Competitors 37

Grifols SA-Key Employees 38

Grifols SA-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 44

Strategy And Business Planning 44

Sep 24, 2018: Grifols Announces the Opening of Biotest Pharmaceuticals Corporation's Newest Plasma Donor Center in Bowling Green, Ohio 44

Financial Announcements 45

Jul 27, 2018: Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7% 45

May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales 50

Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 53

Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 57

May 03, 2017: Bioscience Division sales increase 15% to drive Grifols' revenue growth by 11% to Euros 1,062 million 63

Feb 28, 2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 67

Corporate Communications 75

Apr 17, 2018: Grifols donates over 25 million international units of blood clotting factor in 2017 75

Apr 17, 2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program 76

Legal and Regulatory 77

Jun 08, 2018: Grifols' Building Receives LEED Certification 77

Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on '688 Patent 78

Government and Public Interest 79

Oct 08, 2018: Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support 79

Sep 22, 2017: An ISCIII researcher awarded for her work on Alpha-1 Antitrypsin Deficiency (DAAT) 80

Jun 24, 2017: Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation's John W. Walsh Research Fund 81

Product News 82

Jun 22, 2017: Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples 82

Other Significant Developments 83

Jul 05, 2018: Grifols, the newest angel of elBullifoundation 83

Jun 28, 2018: Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2017 84

May 25, 2018: Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends 85

May 23, 2018: Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency 87

Appendix 88

Methodology 88

About GlobalData 88

Contact Us 88

Disclaimer 88


List Of Figure

List of Figures

Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Grifols SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Grifols SA, Deals By Therapy Area, 2012 to YTD 2018 9

Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10

Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12

Araclon Biotech Enters into Agreement with TFS International 14

Grifols and GigaGen Enter into Research Agreement 15

Grifols Enters into Agreement with MassBiologics 16

Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17

Grifols Enters Into Licensing Agreement With Aradigm 18

ThromboGenics Enters into Licensing Agreement with Grifols 20

Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21

Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 23

Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24

Grifols Completes Public Offering Of Bonds Due 2022 For USD 1 Billion 25

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27

Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28

Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29

Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30

Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31

Alken Asset Management Sells 2.72% Stake In Grifols For USD 227 Million 32

Grifols Completes Acquisition Of 35% Stake In Aradigm For USD 26 Million 33

Grifols Acquires 60% Stake In Progenika Biopharma For USD 48 Million 34

Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35

Grifols Acquires 51% Stake In Araclon Biotech 36

Grifols SA, Key Competitors 37

Grifols SA, Key Employees 38

Grifols SA, Other Locations 39

Grifols SA, Subsidiaries 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Grifols SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. The company offers its products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA (GRF)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10

Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Grifols SA, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12

Partnerships 14

Araclon Biotech Enters into Agreement with TFS International 14

Grifols and GigaGen Enter into Research Agreement 15

Grifols Enters into Agreement with MassBiologics 16

Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17

Licensing Agreements 18

Grifols Enters Into Licensing Agreement With Aradigm 18

ThromboGenics Enters into Licensing Agreement with Grifols 20

Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21

Equity Offering 22

Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 23

Debt Offering 24

Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24

Grifols Completes Public Offering Of Bonds Due 2022 For USD 1 Billion 25

Acquisition 26

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27

Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28

Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29

Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30

Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31

Alken Asset Management Sells 2.72% Stake In Grifols For USD 227 Million 32

Grifols Completes Acquisition Of 35% Stake In Aradigm For USD 26 Million 33

Grifols Acquires 60% Stake In Progenika Biopharma For USD 48 Million 34

Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35

Grifols Acquires 51% Stake In Araclon Biotech 36

Grifols SA-Key Competitors 37

Grifols SA-Key Employees 38

Grifols SA-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 44

Strategy And Business Planning 44

Sep 24, 2018: Grifols Announces the Opening of Biotest Pharmaceuticals Corporation's Newest Plasma Donor Center in Bowling Green, Ohio 44

Financial Announcements 45

Jul 27, 2018: Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7% 45

May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales 50

Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 53

Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 57

May 03, 2017: Bioscience Division sales increase 15% to drive Grifols' revenue growth by 11% to Euros 1,062 million 63

Feb 28, 2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 67

Corporate Communications 75

Apr 17, 2018: Grifols donates over 25 million international units of blood clotting factor in 2017 75

Apr 17, 2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program 76

Legal and Regulatory 77

Jun 08, 2018: Grifols' Building Receives LEED Certification 77

Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on '688 Patent 78

Government and Public Interest 79

Oct 08, 2018: Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support 79

Sep 22, 2017: An ISCIII researcher awarded for her work on Alpha-1 Antitrypsin Deficiency (DAAT) 80

Jun 24, 2017: Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation's John W. Walsh Research Fund 81

Product News 82

Jun 22, 2017: Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples 82

Other Significant Developments 83

Jul 05, 2018: Grifols, the newest angel of elBullifoundation 83

Jun 28, 2018: Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2017 84

May 25, 2018: Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends 85

May 23, 2018: Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency 87

Appendix 88

Methodology 88

About GlobalData 88

Contact Us 88

Disclaimer 88


List Of Figure

List of Figures

Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Grifols SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Grifols SA, Deals By Therapy Area, 2012 to YTD 2018 9

Grifols SA, Medical Devices Deals, 2012 to YTD 2018 10

Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12

Araclon Biotech Enters into Agreement with TFS International 14

Grifols and GigaGen Enter into Research Agreement 15

Grifols Enters into Agreement with MassBiologics 16

Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 17

Grifols Enters Into Licensing Agreement With Aradigm 18

ThromboGenics Enters into Licensing Agreement with Grifols 20

Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 21

Grifols to Invest USD4 Million in AlbaJuna Therapeutics 22

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 23

Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 24

Grifols Completes Public Offering Of Bonds Due 2022 For USD 1 Billion 25

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Grifols Shared Services North America Acquires 51% Stake in Goetech (MedKeeper) 27

Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 28

Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 29

Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 30

Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 31

Alken Asset Management Sells 2.72% Stake In Grifols For USD 227 Million 32

Grifols Completes Acquisition Of 35% Stake In Aradigm For USD 26 Million 33

Grifols Acquires 60% Stake In Progenika Biopharma For USD 48 Million 34

Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 35

Grifols Acquires 51% Stake In Araclon Biotech 36

Grifols SA, Key Competitors 37

Grifols SA, Key Employees 38

Grifols SA, Other Locations 39

Grifols SA, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Grifols SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.